Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences, Inc. (OTCQB: ACUT) is a clinical stage diagnostics company focused on molecular tests for patients with, or at risk of, cancer. Its news flow centers on the development, validation, and commercialization of proprietary assays such as the StemPrintER test for early stage breast cancer and the MicroRNA Signature Classifier (MSC) test for lung cancer risk assessment.
Readers of this news page can follow updates on AccuStem’s collaborations with research groups and diagnostic laboratories, including agreements with the National Surgical Adjuvant Breast and Bowel Project (NSABP) to evaluate StemPrintER and partnerships with EmeritusDX to expand blood-based testing capabilities and deploy the MSC test in clinical settings. Coverage also includes announcements related to clinical trial access, such as the development agreement tied to the Rete Italiana di Screening Polmonare (RISP) lung cancer screening trial.
In addition to scientific and clinical milestones, AccuStem’s news includes corporate and investor-related items, such as insider share purchases by its Chairman and participation in virtual investor conferences where the company discusses its diagnostic portfolio and oncology focus. Regulatory and reimbursement developments, including steps toward local coverage determinations for the MSC test, are also disclosed through official channels.
This page aggregates these company-specific updates so investors, clinicians, and other interested readers can review AccuStem’s reported progress in oncology diagnostics, its partnerships, and its stated efforts to integrate tests like StemPrintER and MSC into cancer screening, treatment planning, and monitoring workflows.
AccuStem Sciences (OTCQB: ACUT) executed a pilot study agreement with NSABP to evaluate the StemPrintER test in a subset of patients from the NSABP B-32 cohort. StemPrintER interrogates 20 genes to stratify early-stage breast cancer patients by tumor "stemness" to assess recurrence risk. Prior studies cited show "High Stemness" patients are up to 4x more likely to experience distant recurrence than "Low Stemness" patients. The pilot will assess sample viability and predictive utility in the surgical setting and enable subsequent confirmation across the full B-32 cohort of over 5,000 enrolled patients.
AccuStem Sciences (OTCQB: ACUT) announced an expansion of blood-based testing capabilities through its partnership with EmeritusDX. The collaboration includes the installation of the Promega Maxwell RSC system at EmeritusDX for high-throughput microRNA extraction from blood samples.
This expansion will support AccuStem's MSC test, the first diagnostic using microRNAs to stratify lung nodules for malignancy risk. Additionally, EmeritusDX has increased its sales force by 35% and launched the Syntara™ platform for personalized treatment strategies in hematologic diseases.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer outcomes, has announced that CEO Wendy Blosser will present at the Life Sciences Virtual Investor Forum on September 18th, 2025 at 2:30 PM EST.
The interactive online presentation will showcase AccuStem's product portfolio, which focuses on innovative molecular testing and tumor "stemness" analysis for cancer screening, treatment, and monitoring. Investors can participate in real-time Q&A and schedule one-on-one meetings from September 19-24. An archived webcast will be available for those unable to attend live.
AccuStem Sciences (OTCQB: ACUT) and EmeritusDX have expanded their strategic partnership to commercialize the MSC test for lung cancer screening. The test analyzes 24 microRNAs to differentiate between high and low-risk lung nodules identified through low-dose computed tomography (LDCT).
The partnership aims to enhance lung nodule stratification accuracy, improve patient outcomes, and reduce healthcare costs. The companies plan to launch the MSC test in US clinics in 2026, targeting the 1.6 million patients diagnosed annually with lung nodules in the United States.
The collaboration will utilize EmeritusDX's CLIA-certified laboratory and commercial infrastructure alongside AccuStem's cancer screening technologies. Both companies will pursue reimbursement strategies to broaden access to the MSC test.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased an additional 5,000 shares of ACUT stock in the open market. This acquisition increases Cerrone's total holdings to 4,915,759 shares of the company.
AccuStem Sciences (OTCQB: ACUT) has signed a development agreement to access blood samples from the Rete Italiana di Screening Polmonare (RISP) clinical trial for its microRNA Signature Classifier (MSC) test development. The trial spans 18 centers in Italy.
The MSC test analyzes 24 miRNAs in plasma samples from patients with lung nodules to enhance low dose computed tomography (LDCT) screening accuracy. The MILD trial showed that combining MSC with LDCT could reduce false positive rates by a factor of five. The test has been validated across 5,000+ patients in multiple prospective trials.
The agreement includes statistical and analytical support to help AccuStem establish and commercialize the MSC test in the US, with a planned launch in 2026. The technology aims to improve patient triage, enhance outcomes, and reduce healthcare costs when used in conjunction with LDCT screening.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased 38,000 additional company shares in the open market. This acquisition increases Cerrone's total holdings to 4,910,759 shares.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that Board Chairman Gabriele Cerrone has increased his stake in the company. The Chairman purchased 152,802 additional ACUT shares through open market transactions, bringing his total shareholding to 4,872,759 shares.
FAQ
What is the current stock price of ACCUSTEM SCIENCES (ACUT)?
What is the market cap of ACCUSTEM SCIENCES (ACUT)?
